Yubo International Biotech Limited
YBGJ
$0.01
$0.00-16.00%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -100.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -100.00% |
| Cost of Revenue | 197.67% | -- | -- | -- | -202.38% |
| Gross Profit | 90.70% | -- | -- | -- | -76.24% |
| SG&A Expenses | -45.85% | -39.41% | -18.63% | 35.76% | -21.57% |
| Depreciation & Amortization | 4.72% | -12.10% | 0.67% | -4.09% | -63.16% |
| Other Operating Expenses | 212.13% | -69.34% | -120.94% | -50.41% | -47.14% |
| Total Operating Expenses | -15.64% | -50.07% | -58.27% | 13.18% | -34.58% |
| Operating Income | 19.12% | 50.07% | 58.27% | -14.14% | 31.76% |
| Income Before Tax | 19.04% | 50.06% | 58.27% | -14.11% | 31.79% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 19.04% | 50.06% | 58.27% | -14.11% | 31.79% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -61.71% | -16.92% | -72.60% | -1.55% | -- |
| Net Income | 9.77% | 52.34% | 56.34% | -15.45% | 44.01% |
| EBIT | 19.12% | 50.07% | 58.27% | -14.14% | 31.76% |
| EBITDA | 22.41% | 53.47% | 62.95% | -16.48% | 22.79% |
| EPS Basic | 37.50% | 60.42% | 56.82% | 88.57% | 44.19% |
| Normalized Basic EPS | 30.77% | 62.07% | 56.00% | 88.24% | 51.85% |
| EPS Diluted | 37.50% | 60.42% | 56.82% | 88.57% | 44.19% |
| Normalized Diluted EPS | 30.77% | 62.07% | 56.00% | 88.24% | 51.85% |
| Average Basic Shares Outstanding | 42.51% | 23.41% | 0.00% | 900.00% | 0.00% |
| Average Diluted Shares Outstanding | 42.51% | 23.41% | 0.00% | 900.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |